Europe Influenza Treatment Market 2020-2030

Bonafide Trust 26-08-2020 100 Pages Figures : 44 Tables : 91
Region : Europe Category : Lifescience Pharmaceutical

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Europe influenza treatment market accounted for $187.6 million in 2019 and will grow by 3.6% annually over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic. Highlighted with 33 tables and 44 figures, this 100-page report “Europe Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country. Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs Based on Influenza Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 6

1.1 Industry Definition and Research Scope 6

1.1.1 Industry Definition 6

1.1.2 Research Scope 7

1.2 Research Methodology 10

1.2.1 Overview of Market Research Methodology 10

1.2.2 Market Assumption 11

1.2.3 Secondary Data 11

1.2.4 Primary Data 11

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on the Market 20

2.2 Major Growth Drivers 22

2.3 Market Restraints and Challenges 26

2.4 Emerging Opportunities and Market Trends 29

2.5 Porter’s Fiver Forces Analysis 33

3 Segmentation of Europe Market by Product Type 37

3.1 Market Overview by Product Type 37

3.2 Oseltamivir Phosphate 39

3.3 Baloxavir Marboxil 40

3.4 Peramivir 41

3.5 Zanamivir 42

3.6 Other Drugs 43

4 Segmentation of Europe Market by Influenza Type 44

4.1 Market Overview by Influenza Type 44

4.2 Influenza A 46

4.3 Influenza B 47

4.4 Influenza C 48

5 Segmentation of Europe Market by Administration Route 49

5.1 Market Overview by Administration Route 49

5.2 Oral Administration 51

5.3 Other Administration Routes 52

6 Segmentation of Europe Market by Distribution Channel 53

6.1 Market Overview by Distribution Channel 53

6.2 Retail Pharmacy 55

6.3 Hospital Pharmacy 56

6.4 Clinics 57

6.5 Online Stores 58

7 European Market 2019-2030 by Country 59

7.1 Overview of European Market 59

7.2 Germany 62

7.3 UK 64

7.4 France 67

7.5 Spain 69

7.6 Italy 71

7.7 Russia 73

7.8 Rest of European Market 75

8 Competitive Landscape 77

8.1 Overview of Key Vendors 77

8.2 New Product Launch, Partnership, Investment, and M&A 80

8.3 Company Profiles 81

AstraZeneca Plc 81

BioCryst Pharmaceuticals Inc. 83

Biondvax 84

Daiichi Sankyo Company 85

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 86

GlaxoSmithKline Plc 87

Mylan N.V 88

Natco Pharma Limited 89

Novartis AG 90

Sanofi 91

Seqirus 92

Teva Pharmaceutical Industries Limited 93

9 Investing in Europe Market: Risk Assessment and Management 94

9.1 Risk Evaluation of Europe Market 94

9.2 Critical Success Factors (CSFs) 97

Related Reports and Products 100

Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. Europe Influenza Treatment Market, 2019-2030, $ mn 19
Figure 6. Impact of COVID-19 on Business 20
Figure 7. Primary Drivers and Impact Factors of Europe Influenza Treatment Market 22
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 25
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 25
Figure 10. Primary Restraints and Impact Factors of Europe Influenza Treatment Market 26
Figure 11. Investment Opportunity Analysis 30
Figure 12. Porter’s Fiver Forces Analysis of Europe Influenza Treatment Market 33
Figure 13. Breakdown of Europe Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 37
Figure 14. Europe Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 38
Figure 15. Europe Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 39
Figure 16. Europe Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 40
Figure 17. Europe Influenza Treatment Market: Peramivir, 2019-2030, $ mn 41
Figure 18. Europe Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 42
Figure 19. Europe Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 43
Figure 20. Breakdown of Europe Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 44
Figure 21. Europe Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 45
Figure 22. Europe Influenza Treatment Market: Influenza A, 2019-2030, $ mn 46
Figure 23. Europe Influenza Treatment Market: Influenza B, 2019-2030, $ mn 47
Figure 24. Europe Influenza Treatment Market: Influenza C, 2019-2030, $ mn 48
Figure 25. Breakdown of Europe Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 49
Figure 26. Europe Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 50
Figure 27. Europe Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 51
Figure 28. Europe Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 52
Figure 29. Breakdown of Europe Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 53
Figure 30. Europe Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 54
Figure 31. Europe Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 55
Figure 32. Europe Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 56
Figure 33. Europe Influenza Treatment Market: Clinics, 2019-2030, $ mn 57
Figure 34. Europe Influenza Treatment Market: Online Stores, 2019-2030, $ mn 58
Figure 35. Breakdown of European Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 60
Figure 36. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 61
Figure 37. Influenza Treatment Market in Germany, 2019-2030, $ mn 62
Figure 38. Influenza Treatment Market in UK, 2019-2030, $ mn 64
Figure 39. Influenza Treatment Market in France, 2019-2030, $ mn 67
Figure 40. Influenza Treatment Market in Spain, 2019-2030, $ mn 69
Figure 41. Influenza Treatment Market in Italy, 2019-2030, $ mn 71
Figure 42. Influenza Treatment Market in Russia, 2019-2030, $ mn 73
Figure 43. Influenza Treatment Market in Rest of Europe, 2019-2030, $ mn 75
Figure 44. Growth Stage of Europe Influenza Treatment Industry over the Forecast Period 77

Table 1. Snapshot of Global Digital Biomarkers Market, 2019-2030 21
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 25
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 33
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 34
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 34
Table 6. Current Challenges of Digital Biomarkers in Medical Settings 37
Table 7. Main Product Trends and Market Opportunities in Global Digital Biomarkers Market 40
Table 8. Global Digital Biomarkers Market by System Component, 2019-2030, $ mn 48
Table 9. Global Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 51
Table 10. Global Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 58
Table 11. Global Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 62
Table 12. Global Digital Biomarkers Market by Application, 2019-2030, $ mn 73
Table 13. Global Digital Biomarkers Market by Development Status, 2019-2030, $ mn 81
Table 14. Global Digital Biomarkers Market by End User, 2019-2030, $ mn 86
Table 15. Global Digital Biomarkers Market by Region, 2019-2030, $ mn 92
Table 16. Leading National Digital Biomarkers Market, 2019 and 2030, $ mn 94
Table 17. North America Digital Biomarkers Market by Country, 2019-2030, $ mn 97
Table 18. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn 101
Table 19. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 101
Table 20. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn 101
Table 21. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn 104
Table 22. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 104
Table 23. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn 104
Table 24. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn 106
Table 25. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 106
Table 26. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn 106
Table 27. Europe Digital Biomarkers Market by Country, 2019-2030, $ mn 110
Table 28. Germany Digital Biomarkers Market by System Component, 2019-2030, $ mn 112
Table 29. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 112
Table 30. Germany Digital Biomarkers Market by End User, 2019-2030, $ mn 112
Table 31. UK Digital Biomarkers Market by System Component, 2019-2030, $ mn 114
Table 32. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 114
Table 33. UK Digital Biomarkers Market by End User, 2019-2030, $ mn 114
Table 34. France Digital Biomarkers Market by System Component, 2019-2030, $ mn 116
Table 35. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 116
Table 36. France Digital Biomarkers Market by End User, 2019-2030, $ mn 116
Table 37. Netherlands Digital Biomarkers Market by System Component, 2019-2030, $ mn 118
Table 38. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 118
Table 39. Netherlands Digital Biomarkers Market by End User, 2019-2030, $ mn 118
Table 40. Italy Digital Biomarkers Market by System Component, 2019-2030, $ mn 120
Table 41. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 120
Table 42. Italy Digital Biomarkers Market by End User, 2019-2030, $ mn 120
Table 43. Russia Digital Biomarkers Market by System Component, 2019-2030, $ mn 122
Table 44. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 122
Table 45. Russia Digital Biomarkers Market by End User, 2019-2030, $ mn 122
Table 46. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, $ mn 124
Table 47. APAC Digital Biomarkers Market by Country, 2019-2030, $ mn 127
Table 48. Japan Digital Biomarkers Market by System Component, 2019-2030, $ mn 131
Table 49. Japan Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 131
Table 50. Japan Digital Biomarkers Market by End User, 2019-2030, $ mn 131
Table 51. China Digital Biomarkers Market by System Component, 2019-2030, $ mn 133
Table 52. China Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 133
Table 53. China Digital Biomarkers Market by End User, 2019-2030, $ mn 133
Table 54. Australia Digital Biomarkers Market by System Component, 2019-2030, $ mn 135
Table 55. Australia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 135
Table 56. Australia Digital Biomarkers Market by End User, 2019-2030, $ mn 135
Table 57. India Digital Biomarkers Market by System Component, 2019-2030, $ mn 137
Table 58. India Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 137
Table 59. India Digital Biomarkers Market by End User, 2019-2030, $ mn 137
Table 60. South Korea Digital Biomarkers Market by System Component, 2019-2030, $ mn 139
Table 61. South Korea Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 139
Table 62. South Korea Digital Biomarkers Market by End User, 2019-2030, $ mn 139
Table 63. Digital Biomarkers Market in Rest of APAC by Country, 2019-2030, $ mn 141
Table 64. South America Digital Biomarkers Market by Country, 2019-2030, $ mn 144
Table 65. Argentina Digital Biomarkers Market by System Component, 2019-2030, $ mn 146
Table 66. Argentina Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 146
Table 67. Argentina Digital Biomarkers Market by End User, 2019-2030, $ mn 146
Table 68. Brazil Digital Biomarkers Market by System Component, 2019-2030, $ mn 148
Table 69. Brazil Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 148
Table 70. Brazil Digital Biomarkers Market by End User, 2019-2030, $ mn 148
Table 71. Chile Digital Biomarkers Market by System Component, 2019-2030, $ mn 150
Table 72. Chile Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 150
Table 73. Chile Digital Biomarkers Market by End User, 2019-2030, $ mn 150
Table 74. MEA Digital Biomarkers Market by Country, 2019-2030, $ mn 154
Table 75. UAE Digital Biomarkers Market by System Component, 2019-2030, $ mn 156
Table 76. UAE Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 156
Table 77. UAE Digital Biomarkers Market by End User, 2019-2030, $ mn 156
Table 78. Saudi Arabia Digital Biomarkers Market by System Component, 2019-2030, $ mn 158
Table 79. Saudi Arabia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 158
Table 80. Saudi Arabia Digital Biomarkers Market by End User, 2019-2030, $ mn 158
Table 81. Israel Digital Biomarkers Market by System Component, 2019-2030, $ mn 160
Table 82. Israel Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 160
Table 83. Israel Digital Biomarkers Market by End User, 2019-2030, $ mn 160
Table 84. Breakdown of Global Market by Key Vendor, 2019, % 164
Table 85. Actigraph LLC: Company Snapshot 167
Table 86. Actigraph LLC: Business Segmentation 167
Table 87. Actigraph LLC: Product Portfolio 168
Table 88. Actigraph LLC: Revenue, 2016-2018, $ mn 168
Table 89. Actigraph LLC: Recent Developments 168
Table 90. Risk Evaluation for Investing in Global Market, 2019-2030 197
Table 91. Critical Success Factors and Key Takeaways 200

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3000
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Europe Influenza Treatment Market 2020-2030

Europe Influenza Treatment Market 2020-2030